TNFRSF4 and breast carcinoma: Several CARs were engineered and the HMFG2 CAR containing a fused CD28 plus OX40 plus CD3 endodomain (HOX HMFG2) together with the IgD linker, to combat glycosylation-independent steric hindrance, was shown to inhibit breast cancer growth in a mouse model.